Healthcare delivery transformation is a commercial challenge, not just a clinical one

Where the real cost and performance drivers sit

Across both public and private healthcare systems, the most significant cost and operational pressures tend to sit across three interconnected areas: 

• Workforce and contingent labour  
• High-volume procedural consumables  
• Medical products used across distributed and non-acute care pathways  

These are very different categories, but the underlying issue is similar. Historic decisions, fragmented demand, and limited visibility can become embedded in the way services are delivered. Once embedded, they are difficult to see as sources of inefficiency because they have become part of “business as usual”. 

The answer is not simply to negotiate harder on price. In many cases, the bigger opportunity sits in understanding demand, challenging variation, and redesigning how the organisation buys and uses resources. 

Workforce: The largest controllable cost lever

Workforce remains the single largest cost driver across most healthcare systems. As demand fluctuates and workforce shortages persist, agency staffing and contingent labour frequently become the operational release valve – providing essential flexibility, but often at a significant premium.

The challenge is that temporary workforce costs are rarely driven by agency rates alone. Multiple suppliers, off-framework bookings, last-minute premium fill, management fees and weak booking controls can all increase cost. Underneath these sit more fundamental questions around demand forecasting, rota planning and how effectively internal staff banks are being used.

Across the NHS, these issues have become increasingly important as providers balance workforce pressures with demanding financial recovery and productivity targets. NHS England guidance has reinforced the need to improve workforce utilisation and reduce reliance on agency staffing. Private providers face similar pressures as outpatient, diagnostic, and decentralised care services expand.

This is why a rate negotiation on its own rarely changes the underlying economics. Rate benchmarking and framework rationalisation can deliver value, but sustainable improvement requires providers to look at the workforce model as a whole. That can mean strengthening internal banks, improving demand forecasting, and rota optimisation, tightening governance around off-contract bookings, and considering vendor-neutral or master vendor arrangements where the supplier landscape is fragmented.

The objective is ultimately to create greater control over how temporary workforce demand is generated and fulfilled. Done well, this can reduce premium spend while improving fill rates, operational stability and service continuity.

Workforce optimisation should therefore be viewed as more than a cost-reduction exercise. It is also a capacity and resilience lever: reducing unnecessary reliance on premium labour while preserving the flexibility healthcare organisations need to respond to changing demand.

Procedural consumables: Tackling embedded complexity

As elective activity increases across acute, ambulatory, and day-case settings, the cumulative cost of procedural consumables becomes increasingly important. While major implants and devices tend to receive significant commercial scrutiny, lower-value items such as surgical packs and procedural consumables can attract less attention despite the scale at which they are used.

Over time, complexity can become embedded. Different clinical preferences lead to additional pack variants and specifications, low-utilisation items remain part of standard configurations, and demand becomes fragmented across products and suppliers. The result is not only higher purchasing costs, but also more inventory to manage and less visibility of what individual procedures actually cost.

This is where focusing on unit price alone can miss the bigger opportunity. A £1 saving on an item used occasionally is immaterial. The same saving across thousands of procedures is not. Equally, removing an item that is routinely included but rarely used can eliminate the cost altogether. This is why utilisation and specification can matter as much as headline unit price.

Procedure-level data provides the starting point. Understanding what is actually being used, where specifications differ, and which items drive cost allows providers to identify opportunities to rationalise SKUs, consolidate volumes, and redesign packs with suppliers. Clinical involvement is critical: the objective is to distinguish variation that is necessary for patient care from complexity that has accumulated without a clear clinical rationale.

The impact extends beyond procurement savings. Simplifying products and packs can reduce waste and inventory complexity, improve operational consistency, and give organisations a clearer view of pathway-level costs.

Medical consumables: Reducing variation without compromising care

The same challenge takes a different form across medical consumables used in wound care, long-term condition management, and other distributed care pathways. As services develop over time, product choice can become increasingly fragmented through historic purchasing decisions, different clinical preferences, and the introduction of new suppliers and products.

Some variation is clinically necessary. But where it is not actively reviewed, organisations can find themselves supporting multiple products that perform similar functions. This reduces purchasing leverage, increases inventory, and training requirements and can create significant differences in the cost of treating otherwise similar patients.

The scale makes this worth addressing. NHS Supply Chain estimates that the NHS spends approximately £8 billion annually on medical equipment and consumables, with billions of pounds of spend still sitting outside consolidated procurement routes. The commercial question is therefore not simply whether an individual product can be bought more cheaply, but whether the overall product mix remains appropriate.

Transparent utilisation data and formulary review can help make that variation visible. Combined with early clinical engagement, this creates a basis for rationalising products and SKUs, consolidating suppliers, and directing demand towards preferred products where there is no clinical reason for variation.

The distinction between necessary and simply “nice to have” variation is important. Standardisation imposed purely as a cost-saving exercise is unlikely to be sustainable. When clinicians can see the utilisation, cost, and rationale behind the choices being made, the conversation shifts from restricting choice to agreeing where choice genuinely adds value.

That can create a simpler product base, stronger commercial leverage, and more consistent utilisation without compromising the clinical requirements that should ultimately determine product choice.

Procurement’s role in enabling healthcare transformation

Across all these areas, one pattern remains consistent: healthcare transformation cannot be sustained through isolated sourcing exercises alone. As healthcare systems focus on improving access, increasing productivity, and delivering more integrated care models, the supporting commercial infrastructure must evolve at the same pace as clinical ambition. 

That requires organisations to move beyond transactional procurement activity towards a more integrated approach: one where long-term financial sustainability is linked to operational productivity improvement, with national targets focused on unlocking billions in efficiency savings over the coming years. Without this, organisations risk continuing to operate reactively, managing rising demand without fundamentally improving cost control, productivity, or capacity resilience. 

The healthcare providers making the strongest progress are typically those treating procurement and supply chain functions as strategic enablers of system-wide transformation, rather than purely purchasing functions.